Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
[DOI] [PMC free article] [PubMed] [Google Scholar] 146.Hirooka K., Yamamoto T., Kiuchi Y
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
it is the result of a system designed to earn trust through consistent excellence
10.1186/1742-2094-8-69 308 YangL.ZhaoW.GongX.YueD.LiuY.TianY.et al (2023)
Q&A with expert Stuart Phillips Unapproved peptides that lack safety and efficacy data carry substantial risks and belong in a laboratory, not your body, Phillips warns
US$ 22.39
US$ 21.37
US$ 29.23
US$ 21.29
US$ 23.87
US$ 29.31
